GeoWealth Management’s TherapeuticsMD TXMD Stock Holding History

GeoWealth Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-250	Closed	-$33K	–	218
2019 Q2	$33K	Buy	+250	New	+$44.8K	0.09%	46

Other funds holding TXMD

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GeoWealth Management's TXMD Position: Q3 2019 in Review

GeoWealth Management sold out of TherapeuticsMD (TXMD) in Q3 2019, closing a stake of 250 shares — an estimated $33K sold.

GeoWealth Management first reported a position in TXMD in Q2 2019 and held it in 1 quarter. The position peaked at $33K in Q2 2019. 150 funds tracked by Wall St. Rank hold TXMD as of Q3 2019.

GeoWealth Management reported no remaining TherapeuticsMD position as of Q3 2019 after selling out during the quarter.
GeoWealth Management sold 250 TherapeuticsMD shares in Q3 2019, an estimated $33K.
GeoWealth Management first reported a position in TherapeuticsMD in Q2 2019 and held it in 1 quarter.
GeoWealth Management's TherapeuticsMD position peaked at $33K in Q2 2019.
150 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2019.

Based on GeoWealth Management's 13F filing for Q3 2019, filed 14 Nov 2019.